Whereas Jubilant Ingrevia is well placed to capitalize on long-term growth opportunities given by the 60 new products pipeline, strong traction in CDMO, import substitution, China+1 policy and commensurate Capex outlay of Rs 20.5bn over FY22-25, said the brokerage.
Subscribe To Our Free Newsletter |